Abstract

Depression in older individuals is a common complex mood disorder with high comorbidity of both psychiatric and physical diseases, associated with high disability, cognitive decline, and increased mortality The factors predicting the risk of late-life depression (LLD) are incompletely understood. The reciprocal relationship of depressive disorder and age- and disease-related processes has generated pathogenic hypotheses and provided various treatment options. The heterogeneity of depression complicates research into the underlying pathogenic cascade, and factors involved in LLD considerably differ from those involved in early life depression. Evidence suggests that a variety of vascular mechanisms, in particular cerebral small vessel disease, generalized microvascular, and endothelial dysfunction, as well as metabolic risk factors, including diabetes, and inflammation that may induce subcortical white and gray matter lesions by compromising fronto–limbic and other important neuronal networks, may contribute to the development of LLD. The “vascular depression” hypothesis postulates that cerebrovascular disease or vascular risk factors can predispose, precipitate, and perpetuate geriatric depression syndromes, based on their comorbidity with cerebrovascular lesions and the frequent development of depression after stroke. Vascular burden is associated with cognitive deficits and a specific form of LLD, vascular depression, which is marked by decreased white matter integrity, executive dysfunction, functional disability, and poorer response to antidepressive therapy than major depressive disorder without vascular risk factors. Other pathogenic factors of LLD, such as neurodegeneration or neuroimmune regulatory dysmechanisms, are briefly discussed. Treatment planning should consider a modest response of LLD to antidepressants, while vascular and metabolic factors may provide promising targets for its successful prevention and treatment. However, their effectiveness needs further investigation, and intervention studies are needed to assess which interventions are appropriate and effective in clinical practice.

Highlights

  • The pathophysiology of late-life depression (LLD) is multifactorial and complex

  • Another possibility explaining the association between hyperglycemia and LLD is its involvement via generalized microvascular dysfunction (MVD) [79] and inflammation [113], which both may lead to cerebral small vessel disease (CSVD) [114], and subsequent depression [79,115]

  • Despite these and other findings indicating an association between increased amyloid burden in specific areas, e.g., precuneus/posterior cingulate cortex, and depressive symptoms, in general, depression in Alzheimer’s disease (AD) is different from that in AD [8], psychotic symptoms being more common in vascular depression (VaD) than in AD [153], and several studies failed to identify a relationship between AD pathology and LLD

Read more

Summary

Introduction

The pathophysiology of late-life depression (LLD) is multifactorial and complex This common complex mood disorder involves individuals where the initial depressive episode occurs after age 60–65 in the absence of a previous history of affective illness [1,2]. Earlyonset depression may predispose to LLD by accumulating depressive episodes over a lifetime and is associated with a positive family history of mood disorders, lower cardiovascular risk factors, and lower risk for cognitive decline, while late-onset depression (LOD). Shows a higher risk of cardiovascular risk burden, a higher risk for cognitive decline, and greater treatment resistance [22] These overt differences generated mechanistic hypotheses on the role of vascular and metabolic risk factors and their involvement in the development of LLD [23]. LLD is underdiagnosed and inadequately treated [2]

The “Vascular Depression Hypothesis”
Clinical Features of Vascular Depression
VaD and Cognitive Impairment
Cerebral Small Vessel Disease
Impaired Cerebral Hemodynamics
Metabolic Risk Factors
Neurodegeneration
10. Structural Brain Lesions in VaD
11. Challenging Pathomechanisms
12. Implications for Clinical Practice and Management
Findings
13. Conclusions and Outlook
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.